“As many exhibits blue man group of these blue man displays markersare believed to be important to the progress of multiple cancers, this positionsthe VeraTag platform for an important role in patient selection and clinicaldevelopment across a broad spectrum of cancer therapy.” In 2009, Monogram`s plans for further developing its oncology franchiseinclude:* Confirm the results of the Lipton Study in an additional patient cohort tofurther validate the clinical utility of HERmark as a predictor of response totrastuzumab for patients with metastatic breast cancer. A study of approximately500 patients is underway with the Dana Farber Cancer Institute and additionalstudies are under discussion. * Extend the Lipton Study in metastatic breast cancer by making additionalVeraTag measurements, such as those for p95, HER3 and HER heterodimers, inexisting patient samples to investigate the relationship between thosebiomarkers and clinical outcomes, and subsequently submitting study results forpresentation and publication. * Extend the FINHER adjuvant study by making additional VeraTag measurements,such as those for p95, HER3 and HER heterodimers, in existing patient samples toinvestigate the relationship between those biomarkers and clinical outcomes, andsubsequently submitting study results for presentation and publication. * Drive additional adoption of HERmark by oncologists through educating thephysician community about the clinical utility of HERmark. * Present HERmark and its clinical utility to payers to obtain reimbursement. * Conduct additional studies in both metastatic and adjuvant breast cancer usingan expanded menu of VeraTag assays (which may include: HER2 total protein andhomodimer, HER1 total protein and homodimer, HER3 total protein, HER1:2 andHER2:3 heterodimers, HER3-PI3K, and p95) to investigate why patients failtargeted therapies, and thus to understand how targeted inhibitors of theEGFR-family of receptors might be combined for better patient outcomes.

* Incorporate into HERmark, to supplement the current measurements of HER2 totalprotein and HER2:HER2 homodimer levels, at least one additional marker ofpotential resistance to HER2 antagonists such as trastuzumab blue man group tickets . * Work with biopharmaceutical companies to incorporate VeraTag assays into theirphase I, phase II and phase III clinical development programs for cancertherapies that target markers in the EGFR/HER family.”We are excited about the multiple opportunities for establishing VeraTag as animportant tool in the development and use of targeted cancer therapies,”continued Young blue man show . “Clinically validating HERmark and extending it frommeasurements of HER2 status to a broader assessment of tumor status has thepotential to make HERmark a very important tool for oncologists blue man tickets . Similarly, theavailability of an expanded range of VeraTag assays has the potential to open upopportunities across multiple cancer types and therapies.” Compliance with Nasdaq Continued Listing RequirementsMonogram announced its receipt of a notification dated January 15, 2009 from TheNasdaq Stock Market, which stated that Monogram had regained compliance withNasdaq requirements for continued listing on the Nasdaq Stock Market blueman group . In December 2008, Monogram announced its receipt of a letter from The NasdaqStock Market, which stated that the market value of the Company`s listedsecurities had been below the minimum $50 million requirement for continuedinclusion on the Nasdaq Global Market. Today`s notification from The NasdaqStock Market acknowledged that the market value of the Company`s listedsecurities had been above the $50 million threshold for more than 10 consecutivebusiness days, and that the Company had therefore regained compliance withMarketplace Rule 4450(b)(1)(A) Blue Man Group tickets .

About MonogramMonogram is advancing individualized medicine by discovering, developing andmarketing innovative products to guide and improve treatment of seriousinfectious diseases and cancer blue man group show . The Company’s products are designed to helpdoctors optimize treatment regimens for their patients that lead to betteroutcomes and reduced costs bluemangroup . The Company’s technology is also being used bynumerous biopharmaceutical companies to develop new and improved anti-viraltherapeutics and vaccines as well as targeted cancer therapeutics the blue man . Moreinformation about the Company and its technology can be found on its web site at bluemangroup tickets . Forward Looking StatementsCertain statements in this press release are forward-looking, includingstatements regarding the demand and outlook for our products, including ourTrofile and HERmark assays, our projected assets and revenues and our expectedcompliance with Nasdaq listing requirements, potential proceedings to delist ourcommon stock from Nasdaq.

These forward-looking statements are subject to risksand uncertainties and other factors, which may cause actual results to differmaterially from the anticipated results or other expectations expressed in suchforward-looking statements . These risks and uncertainties include, but are notlimited to: risks and uncertainties relating to the performance and acceptanceof our products; the growth in revenues from all products, including Trofile,growth in deferred revenues; the size, timing and success or failure of anyclinical trials for CCR5 inhibitors, entry inhibitors or integrase inhibitors;the risk that our VeraTag assays, including HERmark, may not predict response toparticular therapeutic agents; the risk that we may not be able to obtainadditional cohorts of patient samples for additional VeraTag studies, ourability to successfully conduct clinical studies and the results obtained fromthose studies; whether larger confirmatory clinical studies will confirm theresults of initial studies; expected reliance on a few customers for themajority of our revenues; the renewal of certain customer agreements, includingthe Pfizer collaboration for the ex-US distribution of Trofile; the impact ofcompetition; whether payers will authorize reimbursement for our products andservices and the amount of such reimbursement that may be allowed; whether theFDA or any other agency will decide to further regulate our products orservices, including Trofile; whether the draft guidance on Multivariate IndexAssays issued by the FDA will be subsequently determined to apply to our currentor planned products; whether we will encounter problems or delays in automatingour processes; the ultimate validity and enforceability of our patentapplications and patents; the possible infringement of the intellectual propertyof others; whether licenses to third party technology will be available; whetherwe are able to build brand loyalty and expand revenues; restrictions on theconduct of our business imposed by the Pfizer, G.E bluemengroup Blue Man Group tickets – wikipedia . and other debt agreements;the impact of additional dilution if our convertible debt is converted toequity; and whether we will be able to raise sufficient capital in the future,if required bluemen group . For a discussion of other factors that may cause actual events todiffer from those projected, please refer to our most recent annual report onForm 10-K and quarterly reports on Form 10-Q, as well as other subsequentfilings with the Securities and Exchange Commission Blue Man Group tickets – blueman .

21Hey, you gotta give the probably Big East champion a number before their name…right?Justin Potts No 21Toby Parker No. FCStone CEO Pete Anderson said Thursday that aside from theimpact of credit-challenged commodities markets and the energytrading account, the company was on solid footing. China’s benchmark Shanghai Composite Index .SSEC tumbled65 percent in 2008, for the worst performance of the world’smajor stock markets Blue Man Group tickets – blueman . In May 2007, Danone formally initiated aproceeding, claiming that Wahaha’s establishment of non-joint ventures as wellas the illegal use of “Wahaha” trademark had seriously violated thenon-compete clause.

Michael Swartzburg, President and CEO of Cardiac Network Inc.About Cardiovascular DiseaseCardiovascular disease and coronary heart disease are widespread,afflicting over 70 million people Each year, about 1.1 million Americanssuffer a heart attack. * The key Tokyo Commodity Exchange rubber contract forSeptember delivery closed at 175 Blue Man Group tickets .8 yen per kg, down 1.0yen or 0.6 percent from the previous close It earlier rose ashigh as 178.2 yen. Distract A-rod by Yelling out “Kate!” not “Aha!” (come on that’s funny!). Forest Products Stock Indexof the 27 largest forest company stocks fell 41.16% to 50.59 from the sameperiod a year ago, as reported Monday at market’s closing by Forestweb, theleading independent provider of business intelligence for the forest productssector, which includes timberlands, pulp and paper, packaging and woodproducts.Among the most active stocks in the Forestweb iiStock Index is Smurfit-Stone Container Corp. EAGAN, Minn Blue Man Group tickets ., Jan 28 /PRNewswire/ — It’s that time of year again. The standard, initiallydeveloped for commercial and industrial applications, may be leveraged inresidential settings to reduce cost, promote interoperability among DRtechnologies and allow utilities and energy providers to better manage pricingand critical load issues while actively engaging their consumers. Sales Drivers by Verticals * Other Reports in this Series * List of ExhibitsFor more information visit http:// WoodSenior Fax from USA: 646-607-1907Fax from rest of the world: +353-1-481-1716 Copyright Business Wire 2009.